Sairah Ahmed, MD

Sairah Ahmed, MD, is an associate professor in the Department of Lymphoma/Myeloma, of the Division of Cancer Medicine, and director of the CAR T Program at The University of Texas MD Anderson Cancer Center.

Articles

Positioning CAR T Therapy in Marginal Zone Lymphoma: Efficacy, Safety, and Comparative Insights

December 4th 2025

Panelists discuss how CAR T therapy is being positioned within the treatment paradigm for marginal zone lymphoma based on emerging efficacy and safety data.

Efficacy and Safety Data for CAR T Therapies in Marginal Zone Lymphoma

December 4th 2025

Panelists discuss how emerging evidence supports the use of CAR T therapy for patients with relapsed or refractory marginal zone lymphoma.

Unmet Clinical Needs in Relapsed/Refractory Marginal Zone Lymphoma

November 25th 2025

Panelists discuss how clinicians identify and address ongoing unmet needs in treating relapsed or refractory marginal zone lymphoma.

Current Treatment Landscape in Relapsed/Refractory Marginal Zone Lymphoma

November 25th 2025

Panelists discuss how the treatment landscape for relapsed or refractory marginal zone lymphoma continues to evolve with emerging targeted and immune-based therapies.

Novel CAR T Strategies Under Investigation for Follicular Lymphoma

November 18th 2025

Panelists discuss how novel CAR T strategies are being studied to further improve outcomes in follicular lymphoma.

Toxicities and Risk Mitigation: Comparing CAR T Therapies in Relapsed/Refractory Follicular Lymphoma

November 18th 2025

Panelists discuss how clinicians compare safety profiles and manage risks between different CAR T therapies for relapsed or refractory follicular lymphoma.

Safety Considerations for CAR T Versus Bispecific Antibody Therapies in Relapsed/Refractory Follicular Lymphoma

November 11th 2025

Panelists discuss how safety profiles differ between CAR T therapy and bispecific antibodies for patients with relapsed or refractory follicular lymphoma.

Factors Guiding Therapy Choice: CAR T vs Bispecific Antibodies in Relapsed/Refractory Follicular Lymphoma

November 11th 2025

Panelists discuss how clinicians decide between CAR T therapy and bispecific antibodies for patients with relapsed or refractory follicular lymphoma.

Determining the Optimal Timing of CAR T in Relapsed/Refractory Follicular Lymphoma

November 4th 2025

Panelists discuss how determining the best timing for CAR T therapy can maximize outcomes in relapsed or refractory follicular lymphoma.

Clinical and Disease Factors Influencing CAR T Effectiveness in Relapsed/Refractory Follicular Lymphoma

November 4th 2025

Panelists discuss how individual and disease-specific factors influence the success of CAR T therapy in relapsed or refractory follicular lymphoma.

Pivotal Clinical Trial Evidence Supporting CAR T Use in Relapsed/Refractory Follicular Lymphoma

October 28th 2025

Panelists discuss how pivotal trials have established the efficacy and safety of CAR T therapies for relapsed or refractory follicular lymphoma.

Clinical Considerations for CAR T Use in Relapsed/Refractory Follicular Lymphoma

October 28th 2025

Panelists discuss how clinicians determine when and how to use CAR T-cell therapy in relapsed or refractory follicular lymphoma.

Integrating CAR T and Bispecific Antibodies in Treatments of Relapsed/Refractory Follicular Lymphoma

October 21st 2025

Panelists discuss how CAR T-cell therapy and bispecific antibodies are being integrated into care for relapsed or refractory follicular lymphoma.

Benefits and Limits of Early-Line Treatments in Follicular Lymphoma

October 21st 2025

Panelists discuss how clinicians evaluate the advantages and limitations of therapies used in earlier lines of follicular lymphoma treatment.

Preferred Second-Line Treatment Strategies in Relapsed/Refractory Follicular Lymphoma

October 14th 2025

Panelists discuss how clinicians approach selecting the most appropriate second-line treatments for relapsed or refractory follicular lymphoma.

Current Treatment Landscape in Relapsed/Refractory Follicular Lymphoma

October 14th 2025

Panelists discuss how advances in the understanding of follicular lymphoma have shaped evolving treatment strategies for patients with relapsed or refractory disease.

Dr Ahmed on the Safety Profile of NKTR-255 in Relapsed/Refractory LBCL

April 23rd 2025

Sairah Ahmed, MD, discusses safety data with NKTR-255 in patients with relapsed/refractory large B-cell lymphoma.

Dr Ahmed on the Rationale for Evaluating NTKR-255 After CAR T-Cell Therapy in R/R LBCL

April 10th 2025

Sairah Ahmed, MD, explains the rationale for evaluating NTKR-255 after CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

Dr Ahmed on Challenges Treating Patients With R/R LBCL Following Exposure to CAR T-Cell Therapy

March 5th 2025

Sairah Ahmed, MD, discusses treatment challenges for patients with relapsed/refractory large B-cell lymphoma following CAR T-cell therapy.

Dr Ahmed on NKTR-255 With CD19-Directed CAR T-Cell Therapy in R/R LBCL

February 14th 2025

Sairah Ahmed, MD, discusses evaluating NKTR-255 in combination with CD19-directed CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.